← Back to search
SPEXIS AG
ALLSCHWIL
UnclaimedClaim this profile (free)
Subcontracting experience
4 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Subcontractor | Department of Health and Human Services | SPEXIS HAS DISCOVERED A NOVEL CLASS OF ANTIBIOTICS, THE OUTER MEMBRANE PROTEIN TARGETING ANTIBIOTIC (OMPTA) USING ITS PROPRIETARY MACROCYCLE TECHNOLOGY PLATFORM. OMPTAS ARE BACTERICIDAL AND THEIR MODE OF ACTION INVOLVES BINDING TO BOTH LIPOPOLYSACCHARIDE (LPS) AND OUTER MEMBRANE PROTEINS (OM), RESULTING IN HIGH SELECTIVITY TOWARDS THE MOST CRITICAL GRAM-NEGATIVE PATHOGENS. WHILE MUREPAVADIN, THE FIRST ANTIBIOTIC OF THIS CLASS TO REACH THE CLINICAL DEVELOPMENT STAGE, IS SELECTIVE FOR P. AERUGINOSA BY INHIBITING LPTD, THE SECOND GENERATION OF OMPTAS EXHIBIT A BROAD-SPECTRUM ACTIVITY AGAINST GRAM-NEGATIVE ESKAPE PATHOGENS AND TARGETS THE BAM COMPLEX (BAMA). THE THIRD CLASS OF OMPTAS ARE SELECTIVE AGAINST ENTEROBACTERIACEAE BY INTERACTION WITH THE INTERMEMBRANE LPS TRANSPORT PROTEIN A (LPTA). SPEXIS INITIATED THE DEVELOPMENT OF A NOVEL CLASS OF ANTIBIOTICS LPTA-OMPTA BASED ON THE THANATIN SCAFFOLD, AN INSECT ANTIMICROBIAL PEPTIDE. THANATIN ANALOGUES ARE SELECTIVE FOR ENTEROBACTERIACEAE, WHICH CORRELATES WITH HIGH LPTA CONSERVATION WITHIN THIS ORDER. THEY ARE ACTIVE AGAINST CARBAPENEM RESISTANT ENTEROBACTERIACEAE (CRE) AND MDR/XDR/COLISTIN-RESISTANT E. COLI, K. PNEUMONIAE, AND ENTEROBACTER SPP. NO ACTIVITY WAS OBSERVED AGAINST NATURALLY RESISTANT TO ANTIMICROBIAL PEPTIDE BACTERIA (SERRATIA MARCESCENS, PROTEUS SPP.) OR IN SPECIES WHERE LPTA SEQUENCE IS LESS CONSERVED. THE POTENT IN VITRO ACTIVITY TRANSLATED WELL IN VIVO, EITHER IN THE THIGH, PERITONITIS, LUNG, OR URINARY TRACT INFECTION MODELS. PRELIMINARY DMPK AND SAFETY DATA SUGGEST THAT THE BIODISTRIBUTION AND INTERACTION WITH SELECTED RECEPTORS RELATED TO HISTAMINE, CNS, AND BLOOD PRESSURE, CAN BE MODULATED BY MEDICINAL CHEMISTRY. OUR PRIMARY OBJECTIVE DURING LEAD OPTIMIZATION STAGE IS TO GET A BETTER UNDERSTANDING OF THE CLASS OF COMPOUNDS, AND TO PURSUE THE MEDICINAL CHEMISTRY OPTIMIZATION USING THE SAR LEARNINGS TO IMPROVE THE ACTIVITY AND PROPERTIES OF THE LPTA-OMPTAS. OUR SECOND OBJECTIVE IS TO CHARACTERIZE THE SELECTED LEAD CANDIDATES AND TO NOMINATE A CANDIDATE BY END 2023 WITH AN EFFICACY AND SAFETY PROFILE COMPATIBLE WITH DEVELOPMENT. IN ADDITION, THE INVESTIGATION OF THE MODE OF ACTION OF THANATIN WILL BE CONTINUED IN COLLABORATION WITH PROF. ZERBE AT UNIVERSITY OF ZURICH WHO IS PERFORMING BIOCHEMICAL AND BIOSTRUCTURAL STUDIES TO ELUCIDATE THE BINDING MODE OF THANATIN ANALOGUES TO LPTA DERIVED FROM SENSITIVE AND MUTANT STRAINS. THIS SOPHISTICATED NMR APPROACH IS OUTSIDE OF THE SCOPE OF CARB-X. IN PARALLEL, SPEXIS STARTED A MULTI-SPECIES IDENTIFICATION OF MUTATIONS ASSOCIATED WITH RESISTANCE TO ALLOW FOR POTENCY OPTIMIZATION OF THANATIN DERIVATIVES USING A PANEL OF RESISTANT CLONES WITH DEFINED MUTATIONS IDENTIFIED BY WHOLE GENOME SEQUENCING. OUR AIM IS TO COMPLETE LEAD OPTIMIZATION BY END 2023 FOLLOWED BY PRECLINICAL DEVELOPMENT INCLUDING IND-ENABLING TOXICOLOGY STUDIES AND PHASE 1 STUDIES IN MAN. HENCE, LPTA-OMPTA CONSTITUTES A NOVEL CLASS OF ANTIBIOTICS TO TREAT LIFE-THREATENING INFECTIONS CAUSED BY DIFFICULT-TO-TREAT GRAM-NEGATIVE BACTERIA SUCH AS CRE AND POTENTIALLY ADDRESSES A HIGH UNMET MEDICAL NEED. 4500004366 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending | — | $710,800 | Apr 20, 2023 | — – — |
| Subcontractor | Department of Health and Human Services | SPEXIS HAS DISCOVERED A NOVEL CLASS OF ANTIBIOTICS, THE OUTER MEMBRANE PROTEIN TARGETING ANTIBIOTIC (OMPTA) USING ITS PROPRIETARY MACROCYCLE TECHNOLOGY PLATFORM. OMPTAS ARE BACTERICIDAL AND THEIR MODE OF ACTION INVOLVES BINDING TO BOTH LIPOPOLYSACCHARIDE (LPS) AND OUTER MEMBRANE PROTEINS (OM), RESULTING IN HIGH SELECTIVITY TOWARDS THE MOST CRITICAL GRAM-NEGATIVE PATHOGENS. WHILE MUREPAVADIN, THE FIRST ANTIBIOTIC OF THIS CLASS TO REACH THE CLINICAL DEVELOPMENT STAGE, IS SELECTIVE FOR P. AERUGINOSA BY INHIBITING LPTD, THE SECOND GENERATION OF OMPTAS EXHIBIT A BROAD-SPECTRUM ACTIVITY AGAINST GRAM-NEGATIVE ESKAPE PATHOGENS AND TARGETS THE BAM COMPLEX (BAMA). THE THIRD CLASS OF OMPTAS ARE SELECTIVE AGAINST ENTEROBACTERIACEAE BY INTERACTION WITH THE INTERMEMBRANE LPS TRANSPORT PROTEIN A (LPTA).
SPEXIS INITIATED THE DEVELOPMENT OF A NOVEL CLASS OF ANTIBIOTICS LPTA-OMPTA BASED ON THE THANATIN SCAFFOLD, AN INSECT ANTIMICROBIAL PEPTIDE. THANATIN ANALOGUES ARE SELECTIVE FOR ENTEROBACTERIACEAE, WHICH CORRELATES WITH HIGH LPTA CONSERVATION WITHIN THIS ORDER. THEY ARE ACTIVE AGAINST CARBAPENEM RESISTANT ENTEROBACTERIACEAE (CRE) AND MDR/XDR/COLISTIN-RESISTANT E. COLI, K. PNEUMONIAE, AND ENTEROBACTER SPP. NO ACTIVITY WAS OBSERVED AGAINST NATURALLY RESISTANT TO ANTIMICROBIAL PEPTIDE BACTERIA (SERRATIA MARCESCENS, PROTEUS SPP.) OR IN SPECIES WHERE LPTA SEQUENCE IS LESS CONSERVED. THE POTENT IN VITRO ACTIVITY TRANSLATED WELL IN VIVO, EITHER IN THE THIGH, PERITONITIS, LUNG, OR URINARY TRACT INFECTION MODELS. PRELIMINARY DMPK AND SAFETY DATA SUGGEST THAT THE BIODISTRIBUTION AND INTERACTION WITH SELECTED RECEPTORS RELATED TO HISTAMINE, CNS, AND BLOOD PRESSURE, CAN BE MODULATED BY MEDICINAL CHEMISTRY.
OUR PRIMARY OBJECTIVE DURING LEAD OPTIMIZATION STAGE IS TO GET A BETTER UNDERSTANDING OF THE CLASS OF COMPOUNDS, AND TO PURSUE THE MEDICINAL CHEMISTRY OPTIMIZATION USING THE SAR LEARNINGS TO IMPROVE THE ACTIVITY AND PROPERTIES OF THE LPTA-OMPTAS. OUR SECOND OBJECTIVE IS TO CHARACTERIZE THE SELECTED LEAD CANDIDATES AND TO NOMINATE A CANDIDATE BY END 2023 WITH AN EFFICACY AND SAFETY PROFILE COMPATIBLE WITH DEVELOPMENT.
IN ADDITION, THE INVESTIGATION OF THE MODE OF ACTION OF THANATIN WILL BE CONTINUED IN COLLABORATION WITH PROF. ZERBE AT UNIVERSITY OF ZURICH WHO IS PERFORMING BIOCHEMICAL AND BIOSTRUCTURAL STUDIES TO ELUCIDATE THE BINDING MODE OF THANATIN ANALOGUES TO LPTA DERIVED FROM SENSITIVE AND MUTANT STRAINS. THIS SOPHISTICATED NMR APPROACH IS OUTSIDE OF THE SCOPE OF CARB-X. IN PARALLEL, SPEXIS STARTED A MULTI-SPECIES IDENTIFICATION OF MUTATIONS ASSOCIATED WITH RESISTANCE TO ALLOW FOR POTENCY OPTIMIZATION OF THANATIN DERIVATIVES USING A PANEL OF RESISTANT CLONES WITH DEFINED MUTATIONS IDENTIFIED BY WHOLE GENOME SEQUENCING.
OUR AIM IS TO COMPLETE LEAD OPTIMIZATION BY END 2023 FOLLOWED BY PRECLINICAL DEVELOPMENT INCLUDING IND-ENABLING TOXICOLOGY STUDIES AND PHASE 1 STUDIES IN MAN.
HENCE, LPTA-OMPTA CONSTITUTES A NOVEL CLASS OF ANTIBIOTICS TO TREAT LIFE-THREATENING INFECTIONS CAUSED BY DIFFICULT-TO-TREAT GRAM-NEGATIVE BACTERIA SUCH AS CRE AND POTENTIALLY ADDRESSES A HIGH UNMET MEDICAL NEED. 4500004366 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending | — | -$102,422 | Jan 24, 2023 | — – — |
| Subcontractor | Department of Health and Human Services | SPEXIS HAS DISCOVERED A NOVEL CLASS OF ANTIBIOTICS, THE OUTER MEMBRANE PROTEIN TARGETING ANTIBIOTIC (OMPTA) USING ITS PROPRIETARY MACROCYCLE TECHNOLOGY PLATFORM. OMPTAS ARE BACTERICIDAL AND THEIR MODE OF ACTION INVOLVES BINDING TO BOTH LIPOPOLYSACCHARIDE (LPS) AND OUTER MEMBRANE PROTEINS (OM), RESULTING IN HIGH SELECTIVITY TOWARDS THE MOST CRITICAL GRAM-NEGATIVE PATHOGENS. WHILE MUREPAVADIN, THE FIRST ANTIBIOTIC OF THIS CLASS TO REACH THE CLINICAL DEVELOPMENT STAGE, IS SELECTIVE FOR P. AERUGINOSA BY INHIBITING LPTD, THE SECOND GENERATION OF OMPTAS EXHIBIT A BROAD-SPECTRUM ACTIVITY AGAINST GRAM-NEGATIVE ESKAPE PATHOGENS AND TARGETS THE BAM COMPLEX (BAMA). THE THIRD CLASS OF OMPTAS ARE SELECTIVE AGAINST ENTEROBACTERIACEAE BY INTERACTION WITH THE INTERMEMBRANE LPS TRANSPORT PROTEIN A (LPTA).
SPEXIS INITIATED THE DEVELOPMENT OF A NOVEL CLASS OF ANTIBIOTICS LPTA-OMPTA BASED ON THE THANATIN SCAFFOLD, AN INSECT ANTIMICROBIAL PEPTIDE. THANATIN ANALOGUES ARE SELECTIVE FOR ENTEROBACTERIACEAE, WHICH CORRELATES WITH HIGH LPTA CONSERVATION WITHIN THIS ORDER. THEY ARE ACTIVE AGAINST CARBAPENEM RESISTANT ENTEROBACTERIACEAE (CRE) AND MDR/XDR/COLISTIN-RESISTANT E. COLI, K. PNEUMONIAE, AND ENTEROBACTER SPP. NO ACTIVITY WAS OBSERVED AGAINST NATURALLY RESISTANT TO ANTIMICROBIAL PEPTIDE BACTERIA (SERRATIA MARCESCENS, PROTEUS SPP.) OR IN SPECIES WHERE LPTA SEQUENCE IS LESS CONSERVED. THE POTENT IN VITRO ACTIVITY TRANSLATED WELL IN VIVO, EITHER IN THE THIGH, PERITONITIS, LUNG, OR URINARY TRACT INFECTION MODELS. PRELIMINARY DMPK AND SAFETY DATA SUGGEST THAT THE BIODISTRIBUTION AND INTERACTION WITH SELECTED RECEPTORS RELATED TO HISTAMINE, CNS, AND BLOOD PRESSURE, CAN BE MODULATED BY MEDICINAL CHEMISTRY.
OUR PRIMARY OBJECTIVE DURING LEAD OPTIMIZATION STAGE IS TO GET A BETTER UNDERSTANDING OF THE CLASS OF COMPOUNDS, AND TO PURSUE THE MEDICINAL CHEMISTRY OPTIMIZATION USING THE SAR LEARNINGS TO IMPROVE THE ACTIVITY AND PROPERTIES OF THE LPTA-OMPTAS. OUR SECOND OBJECTIVE IS TO CHARACTERIZE THE SELECTED LEAD CANDIDATES AND TO NOMINATE A CANDIDATE BY END 2023 WITH AN EFFICACY AND SAFETY PROFILE COMPATIBLE WITH DEVELOPMENT.
IN ADDITION, THE INVESTIGATION OF THE MODE OF ACTION OF THANATIN WILL BE CONTINUED IN COLLABORATION WITH PROF. ZERBE AT UNIVERSITY OF ZURICH WHO IS PERFORMING BIOCHEMICAL AND BIOSTRUCTURAL STUDIES TO ELUCIDATE THE BINDING MODE OF THANATIN ANALOGUES TO LPTA DERIVED FROM SENSITIVE AND MUTANT STRAINS. THIS SOPHISTICATED NMR APPROACH IS OUTSIDE OF THE SCOPE OF CARB-X. IN PARALLEL, SPEXIS STARTED A MULTI-SPECIES IDENTIFICATION OF MUTATIONS ASSOCIATED WITH RESISTANCE TO ALLOW FOR POTENCY OPTIMIZATION OF THANATIN DERIVATIVES USING A PANEL OF RESISTANT CLONES WITH DEFINED MUTATIONS IDENTIFIED BY WHOLE GENOME SEQUENCING.
OUR AIM IS TO COMPLETE LEAD OPTIMIZATION BY END 2023 FOLLOWED BY PRECLINICAL DEVELOPMENT INCLUDING IND-ENABLING TOXICOLOGY STUDIES AND PHASE 1 STUDIES IN MAN.
HENCE, LPTA-OMPTA CONSTITUTES A NOVEL CLASS OF ANTIBIOTICS TO TREAT LIFE-THREATENING INFECTIONS CAUSED BY DIFFICULT-TO-TREAT GRAM-NEGATIVE BACTERIA SUCH AS CRE AND POTENTIALLY ADDRESSES A HIGH UNMET MEDICAL NEED. 4500004366 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending | — | -$376,120 | Oct 31, 2022 | — – — |
| Subcontractor | Department of Health and Human Services | SPEXIS HAS DISCOVERED A NOVEL CLASS OF ANTIBIOTICS, THE OUTER MEMBRANE PROTEIN TARGETING ANTIBIOTIC (OMPTA) USING ITS PROPRIETARY MACROCYCLE TECHNOLOGY PLATFORM. OMPTAS ARE BACTERICIDAL AND THEIR MODE OF ACTION INVOLVES BINDING TO BOTH LIPOPOLYSACCHARIDE (LPS) AND OUTER MEMBRANE PROTEINS (OM), RESULTING IN HIGH SELECTIVITY TOWARDS THE MOST CRITICAL GRAM-NEGATIVE PATHOGENS. WHILE MUREPAVADIN, THE FIRST ANTIBIOTIC OF THIS CLASS TO REACH THE CLINICAL DEVELOPMENT STAGE, IS SELECTIVE FOR P. AERUGINOSA BY INHIBITING LPTD, THE SECOND GENERATION OF OMPTAS EXHIBIT A BROAD-SPECTRUM ACTIVITY AGAINST GRAM-NEGATIVE ESKAPE PATHOGENS AND TARGETS THE BAM COMPLEX (BAMA). THE THIRD CLASS OF OMPTAS ARE SELECTIVE AGAINST ENTEROBACTERIACEAE BY INTERACTION WITH THE INTERMEMBRANE LPS TRANSPORT PROTEIN A (LPTA).
SPEXIS INITIATED THE DEVELOPMENT OF A NOVEL CLASS OF ANTIBIOTICS LPTA-OMPTA BASED ON THE THANATIN SCAFFOLD, AN INSECT ANTIMICROBIAL PEPTIDE. THANATIN ANALOGUES ARE SELECTIVE FOR ENTEROBACTERIACEAE, WHICH CORRELATES WITH HIGH LPTA CONSERVATION WITHIN THIS ORDER. THEY ARE ACTIVE AGAINST CARBAPENEM RESISTANT ENTEROBACTERIACEAE (CRE) AND MDR/XDR/COLISTIN-RESISTANT E. COLI, K. PNEUMONIAE, AND ENTEROBACTER SPP. NO ACTIVITY WAS OBSERVED AGAINST NATURALLY RESISTANT TO ANTIMICROBIAL PEPTIDE BACTERIA (SERRATIA MARCESCENS, PROTEUS SPP.) OR IN SPECIES WHERE LPTA SEQUENCE IS LESS CONSERVED. THE POTENT IN VITRO ACTIVITY TRANSLATED WELL IN VIVO, EITHER IN THE THIGH, PERITONITIS, LUNG, OR URINARY TRACT INFECTION MODELS. PRELIMINARY DMPK AND SAFETY DATA SUGGEST THAT THE BIODISTRIBUTION AND INTERACTION WITH SELECTED RECEPTORS RELATED TO HISTAMINE, CNS, AND BLOOD PRESSURE, CAN BE MODULATED BY MEDICINAL CHEMISTRY.
OUR PRIMARY OBJECTIVE DURING LEAD OPTIMIZATION STAGE IS TO GET A BETTER UNDERSTANDING OF THE CLASS OF COMPOUNDS, AND TO PURSUE THE MEDICINAL CHEMISTRY OPTIMIZATION USING THE SAR LEARNINGS TO IMPROVE THE ACTIVITY AND PROPERTIES OF THE LPTA-OMPTAS. OUR SECOND OBJECTIVE IS TO CHARACTERIZE THE SELECTED LEAD CANDIDATES AND TO NOMINATE A CANDIDATE BY END 2023 WITH AN EFFICACY AND SAFETY PROFILE COMPATIBLE WITH DEVELOPMENT.
IN ADDITION, THE INVESTIGATION OF THE MODE OF ACTION OF THANATIN WILL BE CONTINUED IN COLLABORATION WITH PROF. ZERBE AT UNIVERSITY OF ZURICH WHO IS PERFORMING BIOCHEMICAL AND BIOSTRUCTURAL STUDIES TO ELUCIDATE THE BINDING MODE OF THANATIN ANALOGUES TO LPTA DERIVED FROM SENSITIVE AND MUTANT STRAINS. THIS SOPHISTICATED NMR APPROACH IS OUTSIDE OF THE SCOPE OF CARB-X. IN PARALLEL, SPEXIS STARTED A MULTI-SPECIES IDENTIFICATION OF MUTATIONS ASSOCIATED WITH RESISTANCE TO ALLOW FOR POTENCY OPTIMIZATION OF THANATIN DERIVATIVES USING A PANEL OF RESISTANT CLONES WITH DEFINED MUTATIONS IDENTIFIED BY WHOLE GENOME SEQUENCING.
OUR AIM IS TO COMPLETE LEAD OPTIMIZATION BY END 2023 FOLLOWED BY PRECLINICAL DEVELOPMENT INCLUDING IND-ENABLING TOXICOLOGY STUDIES AND PHASE 1 STUDIES IN MAN.
HENCE, LPTA-OMPTA CONSTITUTES A NOVEL CLASS OF ANTIBIOTICS TO TREAT LIFE-THREATENING INFECTIONS CAUSED BY DIFFICULT-TO-TREAT GRAM-NEGATIVE BACTERIA SUCH AS CRE AND POTENTIALLY ADDRESSES A HIGH UNMET MEDICAL NEED. 4500004366 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending | — | $520,548 | Oct 6, 2022 | — – — |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Government-sourced data comes from SAM.gov, SBA and USAspending.gov and is attributed to its source. Items marked company-reported were provided by the company and are verified by FedSub only where labeled. FedSub is a private company and is not affiliated with SBA, GSA/SAM.gov, or any government agency.